Baudax Bio (BXRXQ) Stock Price

Baudax Bio Price

NYSE·CLOSED
0.00
+0.00 (+0.00 %)
Market closed

Revenue has compounded at 61.0% per year over the past 2 years to 1.27 M USD. Baudax Bio's net margin stands at -4,629.9%, up from -15,530.6% several years earlier. The stock trades about 900% above its 52-week low.

Baudax Bio stock price

Access this data via the Eulerpool API

Baudax Bio business model & stock analysis

Frequently asked questions about Baudax Bio

8 analysts currently rate the Baudax Bio stock: 0 recommend buying, 3 holding and 5 selling.

Converted at the current exchange rate, the Baudax Bio share trades at 0.00 EUR (0.00 USD).

No history available for Baudax Bio.

The revenue cannot currently be calculated for Baudax Bio.

The profit cannot currently be calculated for Baudax Bio.

The P/E ratio cannot be calculated for Baudax Bio at the moment.

The P/S cannot be calculated for Baudax Bio currently.

The Eulerpool Quality Score for Baudax Bio is 3/10.

The ISIN of Baudax Bio is US07160F4046. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Baudax Bio is BXRXQ. The ticker symbol is used to trade Baudax Bio shares on the stock exchange.

Baudax Bio paid dividends every year for the past 0 years.

Baudax Bio is assigned to the 'Health' sector.

The dividends of Baudax Bio are distributed in USD.

Fair ValueTerminal
0.00 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Pharmaceuticals
Number of shares
Employees
Revenue per Employee
141,111.11 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Nov 14, 2019
ISIN
US07160F4046
Cusip
07160F404
Market capitalization
52-Week Range
0.00–0.00USD
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2023
-0.00
P/Ee 2024
-0.00
P/Ee 2025
-0.00
P/Ee 2026
-0.00
P/Ee 2027
0.00
P/S
P/Se
—
EV/EBIT
—
P/B Ratio
—
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
343.46 %
Gross Margin
-451.97 %
EBIT Margin
-2,596.06 %
Net Margin
-4,629.92 %
EPS (Earnings Per Share)
-178.18 USD
Net Debt / EBIT
-0.06
Debt/Equity
-0.29
Last updated Sep 27, 2026, 12:27 PM

Baudax Bio Peer Group

All fundamentals and in-depth analysis of Baudax Bio

Our stock analysis for Baudax Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Baudax Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.